Stanford researchers led by Bali Pulendran reported a preclinical intranasal vaccine candidate that protected mice against diverse respiratory viruses, hospital‑acquired bacteria and even allergen challenge. The Science paper describes a mucosal immunization strategy that couples innate and adaptive arms to sustain broad pulmonary protection for months. Investigators emphasized the approach’s novelty relative to antigen‑specific vaccines, showing protection against SARS‑CoV‑2 variants, Staphylococcus aureus, Acinetobacter baumannii and house dust mite allergy in murine models. Authors cautioned the work is preclinical and outlined translational steps needed to test safety and efficacy in humans. If validated in humans, the platform could change seasonal vaccine strategies and pandemic preparedness by shifting emphasis from narrowly targeted antigens to durable mucosal immunity.